BIO-TECHNE ($TECH) posted quarterly earnings results for Q2 2026 on Wednesday, February 4th. The company reported earnings of $0.46 per share, beating estimates of $0.44 by $0.02. The company also reported revenue of $295,880,000, missing estimates of $295,994,667 by $-114,667.
You can see Quiver Quantitative's $TECH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIO-TECHNE Insider Trading Activity
BIO-TECHNE insiders have traded $TECH stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TECH stock by insiders over the last 6 months:
- ROELAND NUSSE sold 17,040 shares for an estimated $960,388
- ROBERT V BAUMGARTNER sold 17,040 shares for an estimated $957,818
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIO-TECHNE Hedge Fund Activity
We have seen 302 institutional investors add shares of BIO-TECHNE stock to their portfolio, and 275 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 5,497,787 shares (-62.1%) from their portfolio in Q3 2025, for an estimated $305,841,890
- WELLINGTON MANAGEMENT GROUP LLP added 3,978,026 shares (+349.8%) to their portfolio in Q3 2025, for an estimated $221,297,586
- MAVERICK CAPITAL LTD added 3,012,654 shares (+inf%) to their portfolio in Q3 2025, for an estimated $167,593,942
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,495,328 shares (+164.4%) to their portfolio in Q4 2025, for an estimated $146,750,239
- CITADEL ADVISORS LLC removed 2,253,683 shares (-91.2%) from their portfolio in Q3 2025, for an estimated $125,372,385
- MILLENNIUM MANAGEMENT LLC removed 1,435,033 shares (-87.5%) from their portfolio in Q3 2025, for an estimated $79,830,885
- DURABLE CAPITAL PARTNERS LP added 1,395,966 shares (+inf%) to their portfolio in Q3 2025, for an estimated $77,657,588
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO-TECHNE Congressional Stock Trading
Members of Congress have traded $TECH stock 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TECH stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 4 times. They made 3 purchases worth up to $45,000 on 12/05, 12/02, 10/22 and 1 sale worth up to $15,000 on 01/28.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIO-TECHNE Analyst Ratings
Wall Street analysts have issued reports on $TECH in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Argus Research issued a "Buy" rating on 11/20/2025
- UBS issued a "Buy" rating on 11/06/2025
- TD Cowen issued a "Buy" rating on 10/14/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Citigroup issued a "Buy" rating on 08/21/2025
To track analyst ratings and price targets for BIO-TECHNE, check out Quiver Quantitative's $TECH forecast page.
BIO-TECHNE Price Targets
Multiple analysts have issued price targets for $TECH recently. We have seen 7 analysts offer price targets for $TECH in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $62.0 on 01/05/2026
- David Toung from Argus Research set a target price of $68.0 on 11/20/2025
- Dan Leonard from UBS set a target price of $70.0 on 11/06/2025
- Brandon Couillard from Wells Fargo set a target price of $70.0 on 11/06/2025
- Kyle Boucher from TD Cowen set a target price of $70.0 on 10/14/2025
- Conor McNamara from RBC Capital set a target price of $73.0 on 09/03/2025
- Patrick Donnelly from Citigroup set a target price of $70.0 on 08/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
